US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Panbela Therapeutics, Inc. - Common Stock (NQ:PBLA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Panbela Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Panbela to Present at the LD Micro Investor Conference
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Smith & Wesson Brands Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket ↗
Gainers Impel Pharmaceuticals Inc. (NASDAQ: IMPL) rose 41.3% to $0.54 in pre-market trading after falling 4% on Thursday. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Pre-market stock movers are a hot topic worth checking out on Friday with a look at the biggest winners and losers today! 
Via InvestorPlace
News headline image
Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
Patent developed in collaboration with Sanofi 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  Wednesday's session saw 150 companies set new 52-week lows. 
Via Benzinga
News headline image
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Panbela to Host Second Quarter 2023 Earnings Conference Call on August 10, 2023
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling
Interim Data Analysis anticipated in Early 2024 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 10, 2023 ↗
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
News headline image
Nasdaq Moves Lower; US Crude Oil Inventories Decline Less Than Projected ↗
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite moving lower on Wednesday. The Dow traded up 0.31% to 35,058.78 while the NASDAQ fell 0.21% to 14,323.99. The S&P 500, also... 
Via Benzinga
News headline image
Why Amarin Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) rose 43% to $6.91. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Are Panbela Therapeutics Shares Trading Higher Today? ↗
Panbela Therapeutics Inc (NASDAQ: PBLA) shares are trading higher after the company divested certain assets in its eflornithine pediatric neuroblastoma program to US WorldMeds 1 (USWM), a... 
Via Benzinga
News headline image
Crude Oil Up 1%; M&T Bank Posts Upbeat Q2 Results ↗
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 0.5% on Wednesday. The Dow traded up 0.53% to 35,137.16 while the NASDAQ rose 0.48% to 14,422.74. The S&P 500,... 
Via Benzinga
News headline image
Dow Rises Over 100 Points; Goldman Sachs Earnings Miss Estimates ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.37% to 35,082.94 while the NASDAQ rose... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Panbela's Diverse Pipeline Is Encouraging Amidst Challenges In Pancreatic Cancer Therapy: Analyst ↗
Panbela Therapeutics Inc (NASDAQ: PBLA) said that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 ASPIRE trial for patients with untreated metastatic pancreatic ductal adenocarcinoma... 
Via Benzinga
News headline image
Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
From Panbela Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
BioMedNewsBreaks – Panbela Therapeutics Inc. (NASDAQ: PBLA) Closes on Public Offering Totaling About $8.5M
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 10 Next >